Table 1.

The relationship between S100A2 mRNA expression and clinical characteristics in endometrial carcinoma

Characteristic	Low expression of S100A2	High expression of S100A2	P value
n	276	276
Clinical stage, n (%)			0.028
Stage I	186 (33.7%)	156 (28.3%)
Stage II	22 (4%)	29 (5.3%)
Stage III	52 (9.4%)	78 (14.1%)
Stage IV	16 (2.9%)	13 (2.4%)
Primary therapy outcome, n (%)			0.864
PD	11 (2.3%)	9 (1.9%)
SD	2 (0.4%)	4 (0.8%)
PR	6 (1.2%)	6 (1.2%)
CR	218 (45.4%)	224 (46.7%)
Race, n (%)			0.549
Asian	10 (2%)	10 (2%)
Black or African   American	60 (11.8%)	48 (9.5%)
White	188 (37.1%)	191 (37.7%)
Age, n (%)			0.766
<=60	101 (18.4%)	105 (19.1%)
>60	174 (31.7%)	169 (30.8%)
Weight, n (%)			0.727
<=80	124 (23.5%)	119 (22.5%)
>80	140 (26.5%)	145 (27.5%)
BMI, n (%)			0.219
<=30	114 (22%)	98 (18.9%)
>30	147 (28.3%)	160 (30.8%)
Histological type, n (%)			0.014
Endometrioid	220 (39.9%)	190 (34.4%)
Mixed	9 (1.6%)	15 (2.7%)
Serous	47 (8.5%)	71 (12.9%)
Residual tumor, n (%)			0.962
R0	198 (47.9%)	177 (42.9%)
R1	12 (2.9%)	10 (2.4%)
R2	8 (1.9%)	8 (1.9%)
Histologic grade, n (%)			0.658
G1	51 (9.4%)	47 (8.7%)
G2	63 (11.6%)	57 (10.5%)
G3	156 (28.8%)	167 (30.9%)
Tumor invasion(%), n (%)			0.402
<50	134 (28.3%)	125 (26.4%)
>=50	102 (21.5%)	113 (23.8%)
Menopause status, n (%)			0.038
Pre	23 (4.5%)	12 (2.4%)
Peri	5 (1%)	12 (2.4%)
Post	221 (43.7%)	233 (46%)
Hormones therapy, n (%)			0.578
No	143 (41.6%)	154 (44.8%)
Yes	20 (5.8%)	27 (7.8%)
Radiation therapy, n (%)			0.177
No	148 (28.1%)	131 (24.9%)
Yes	116 (22%)	132 (25%)
Diabetes, n (%)			0.158
No	155 (34.4%)	173 (38.4%)
Yes	68 (15.1%)	55 (12.2%)